Rapid Medical™ Gains Approval in China for the World’s Only Adjustable Thrombectomy Device
Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval for its TIGERTRIEVER revascularization device. With this milestone of National Medical Product Administration (NMPA) approval, TIGERTRIEVER becomes the first device to offer patient-specific solutions for removing blood clots from the brain to advance the treatment of ischemic stroke.
“This new approval for TIGERTRIEVER propels treatment for ischemic stroke patients in China,” says Ronen Eckhouse, co-founder and CEO at Rapid Medical. “We are fortunate to have an excellent partner with MicroPort Scientific Corporation, who understand the need to expand neurointerventional capabilities and individualized stroke care for these patients.”
TIGERTRIEVER technology, fueled by advancements in aerospace engineering, enables precise control during mechanical thrombectomy. Its unique operation changes these procedures from a passive to an active approach that accelerates clot capture and potentially reduces the risk of vascular injury during removal. Comparable, leading stent retrievers are self-expanding and static, which can lead to suboptimal clot removal and minimal vessel protection.
Published clinical studies demonstrate superiority to conventional stent retrievers. The results of the TIGER multicenter trial presented 3 statistically significant improvements– in restoring blood flow to the brain, good clinical outcomes, and reducing emboli to new territory–compared to an average from six pivotal stent retriever trials.1 Additionally, the TIGER trial showed fast procedure times, on par with aspiration alone2, driven by a very high rate of first-pass success.
“The successful launch of TIGERTRIEVER in China represents another stroke intervention innovation that can be applied in the real world, introducing the concept of tailored thrombectomy using an adjustable stent retriever that allows physicians to navigate procedures and unexpected circumstances with added control,” said Zhiyong Xie, President at MicroPort NeuroTech. “TIGERTRIEVER provides Chinese physicians with a new choice of neurological intervention medical devices that will benefit more patients.”
About Rapid Medical
Rapid Medical holds an exclusive distribution agreement with MicroPort NeuroTech, a subsidiary of MicroPort Scientific Corporation headquartered in China. Rapid Medical pioneers advanced interventional devices to treat neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing proprietary manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the anatomy and tailor the approach to every patient for better procedural outcomes. TIGERTRIEVER™ 13, 17 and 21, COMANECI™ and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER XL is also CE marked. More information is available at www.rapid-medical.com
1 Gupta, Rishi et al. “New Class of Radially Adjustable Stentrievers for Acute Ischemic Stroke: Primary Results of the Multicenter TIGER Trial.” Stroke vol. 52,5 (2021): 1534-1544. doi:10.1161/STROKEAHA.121.034436
2 Turk, Aquilla S 3rd et al. “Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial.” Lancet (London, England)vol. 393,10175 (2019): 998-1008. doi:10.1016/S0140-6736(19)30297-1
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sofinnova Partners Unveils Sofinnova.AI: A Cutting-edge Artificial Intelligence Platform Set to Transform Its Life Sciences Investment Practice5.12.2023 12:30:00 EET | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the launch of Sofinnova.AI, an artificial intelligence platform that seamlessly integrates advanced computational capabilities with the firm’s 50-year-history of industry expertise, one of the world's largest, longitudinal, annotated, proprietary data sets on early-stage life science companies, enabling unprecedented insights into life sciences innovation discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205517503/en/ Sofinnova.AI (Photo: Sofinnova) Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, said: “Sofinnova.AI super-charges the conventional, artisanal approach of sourcing and building investment opportunities — a process that has, until now, been solely reliant on our personal networks and the meticulous task of connecting disparate information over mont
Taulia Adds Bank of China and BNP Paribas to Its Funder Network5.12.2023 11:00:00 EET | Press release
Taulia, a leading provider of working capital management solutions, today announced it has added the Bank of China London Branch, and BNP Paribas to its global multi-funder network. The addition of the two major global banks is the most recent in an already large and growing network of funders available to Taulia’s global customers, enabling businesses to access an increasingly broad and diverse funding pool, with greater choice, liquidity, and availability of capital. Multifunder models within supply chain finance programs are designed to provide resilience through diversification and a wider pool of funding for different currencies, geographies, client sizes, and credit profiles. Combined with the right technology, it also enables businesses to hedge against liquidity risk, particularly during periods of economic uncertainty. Cedric Bru, CEO, Taulia, comments: “Adding Bank of China and BNP Paribas to the Taulia multi-funder network is an enormous achievement, and we are delighted to
PUMA Scale-up Their Textile-to-textile Recycling Technology, Creating All Future Replica Football Kit Using RE:FIBRE Technology5.12.2023 11:00:00 EET | Press release
Global sports company PUMA has today announced that it has scaled up its textile recycling innovation, RE:FIBRE, replacing recycled polyester with RE:FIBRE technology in all PUMA football Club and Federation replica jerseys from 2024 onwards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205250478/en/ Global sports company PUMA has today announced that it has scaled up its textile recycling innovation, RE:FIBRE, replacing recycled polyester with RE:FIBRE technology in all PUMA football Club and Federation replica jerseys from 2024 onwards. (Photo: Business Wire) Since the launch of the pilot in 2022, which saw PUMA produce recycled training jerseys for their sponsored football clubs, RE:FIBRE technology has been used to create Switzerland and Morocco replica kits for the Women’s World Cup as well as Girona’s 2023/24 season Third kit. In 2024, official PUMA football replica jerseys* including those for the Euro and Copa A
Evolito First in UK to Secure CAA Design Organisation Approval for Electric Propulsion Systems5.12.2023 11:00:00 EET | Press release
Evolito Limited, the pioneer of world-leading axial-flux electric motors, power electronics and battery solutions for aerospace applications, has received Design Organisation Approval (DOA) from the UK Civil Aviation Authority for electric propulsion system products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231201483295/en/ Evolito’s D500 Axial Flux Motor: stacked for increased torque and power up to 1 megawatt. (Photo: Business Wire) The UK Civil Aviation Authority’s approval of Evolito as a Design Organisation demonstrates that it is satisfied that Evolito has the technical expertise, facilities and capabilities to design safe and reliable products, and is able to comply with stringent requirements for certification. Evolito is the first company in the UK to achieve this for electric propulsion systems. This accreditation is a significant milestone towards certification of Evolito’s products, as well as supporting cu
Wallarm Reveals Current Threats to API Security, Move to 100% Channel Strategy and New API Attack Management Solution at Black Hat Europe 20235.12.2023 09:00:00 EET | Press release
BLACK HAT EUROPE 2023 – Wallarm, the integrated app and API security company, today announced its upcoming appearance at Black Hat Europe 2023, the Dec. 4 to Dec. 7 conference that provides the latest in research, development and trends in information security. Wallarm executives are hosting a session on Dec. 7 at 12:15 p.m. GMT at ExCeL London and sharing critical insights and recommendations from the latest API ThreatStats™ report. Additionally, Wallarm is discussing its new 100% channel strategy and launching a new API Attack Surface Management solution during Black Hat Europe. Wallarm’s Black Hat appearance comes as interest in API security solutions grows in Europe, with the Europe API security market expected to witness market growth of 31.5% CAGR during the forecast period (2023-2030). This critical opportunity allows Wallarm to build awareness around the need for API and app security, jump-start expansion to the European market and recruit additional channel partners. Key annou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom